Fiera Capital Corp Buys 5,993 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Fiera Capital Corp raised its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 1.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 444,330 shares of the company’s stock after acquiring an additional 5,993 shares during the period. Fiera Capital Corp owned approximately 0.47% of Crinetics Pharmaceuticals worth $12,779,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. MetLife Investment Management LLC boosted its stake in shares of Crinetics Pharmaceuticals by 0.7% during the 1st quarter. MetLife Investment Management LLC now owns 53,414 shares of the company’s stock worth $1,792,000 after purchasing an additional 394 shares during the period. Arizona State Retirement System boosted its position in shares of Crinetics Pharmaceuticals by 1.8% during the first quarter. Arizona State Retirement System now owns 23,899 shares of the company’s stock valued at $802,000 after buying an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Crinetics Pharmaceuticals by 16.2% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,619 shares of the company’s stock valued at $104,000 after buying an additional 505 shares during the period. Xponance Inc. grew its stake in shares of Crinetics Pharmaceuticals by 9.1% during the first quarter. Xponance Inc. now owns 6,857 shares of the company’s stock valued at $230,000 after buying an additional 573 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Crinetics Pharmaceuticals by 3.3% in the second quarter. Assetmark Inc. now owns 18,667 shares of the company’s stock worth $537,000 after buying an additional 603 shares during the period. Institutional investors own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Price Performance

CRNX stock opened at $41.43 on Friday. Crinetics Pharmaceuticals, Inc. has a 1-year low of $24.10 and a 1-year high of $62.53. The business has a 50-day moving average price of $40.32 and a 200 day moving average price of $34.12. The company has a market capitalization of $3.93 billion, a P/E ratio of -9.15 and a beta of 0.25.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.11). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.39 million. During the same quarter last year, the firm posted ($0.96) EPS. On average, analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on shares of Crinetics Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Wednesday, September 24th. Leerink Partners upped their price target on shares of Crinetics Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, September 29th. The Goldman Sachs Group lifted their price objective on shares of Crinetics Pharmaceuticals from $35.00 to $40.00 and gave the company a “neutral” rating in a report on Friday, September 26th. Finally, Morgan Stanley boosted their price objective on shares of Crinetics Pharmaceuticals from $65.00 to $77.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.55.

Insider Activity

In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 4,000 shares of the stock in a transaction on Friday, September 26th. The stock was sold at an average price of $45.00, for a total transaction of $180,000.00. Following the sale, the chief executive officer owned 106,000 shares of the company’s stock, valued at approximately $4,770,000. This trade represents a 3.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew K. Fust sold 16,000 shares of Crinetics Pharmaceuticals stock in a transaction on Friday, September 26th. The shares were sold at an average price of $44.75, for a total value of $716,000.00. Following the completion of the transaction, the director owned 22,836 shares in the company, valued at $1,021,911. This represents a 41.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 66,492 shares of company stock worth $2,420,687. Corporate insiders own 4.60% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.